A Study of ATTR-01 in Participants With Select Epithelial Solid Tumours

ATTR-01 is the experimental drug being studied in the ATTEST clinical trial. The drug is made from a common cold virus that has been changed to only infect and multiply in cancer cells. This virus delivers an immune therapy drug into the cancer that is intended to promote a participant's own immune system to attack the cancer. The first part of this trial (sub-protocol A) is a phase 1 trial including dose escalation and expansion at one or more doses. It is the first time that ATTR-01 will be given to humans. If an optimal dose is identified, additional sub-protocols will be added by to further elicit whether ATTR-01 may successfully treat cancer. Expanded access is not available.

NCT Number	NCT06977737
Lead Sponsor	Accession Therapeutics Limited
Conditions	Solid Tumor, Adult
Enrollment	72 participants
Start Date	2025-03-21
Primary Completion	2029-12-31 (estimated)
Study Completion	2034-12-31 (estimated)
Updated on ClinicalTrials.gov	2026-05-22